The Latest Cancer Agents and Their Complications - 22/07/18
Résumé |
The latest cancer agents, collectively known as cancer immunotherapy, have tremendously increased the armamentarium against cancer. Their targeted mechanisms seem ideal, but they do come with complications. As these therapies become more widespread, emergency physicians everywhere must be aware of the immune-related adverse events that can occur, and be ready to identify and coordinate treatment. This article provides the emergency physician with a brief introduction and overview of immunotherapy drugs and their complications.
Le texte complet de cet article est disponible en PDF.Keywords : Cancer, Immunotherapy, Checkpoint modulators, Cancer vaccines, Adoptive immunotherapy, CAR-T, Immune-related adverse events, Oncologic emergency
Plan
Disclosure Statement: The author reports no relationship with a commercial company that has a direct financial interest in subject matter or materials discussed in this article or with a company making a competing product. |
Vol 36 - N° 3
P. 485-492 - août 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?